IRMD — IRadimed Corporation stock price, charts and financials

Latest market price

93.13

+1.57+1.71%

Overview Short InterestFilings

IRMDQT53IRadimed Corporation·NASDAQ

Overview Short InterestFilings

93.13+1.71%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AVNS+0.04%$24.99 AORT-2.08%$26.90 PRCT-0.54%$18.28 TNDM+0.45%$20.20 IART+0.11%$17.90 CNMD-2.82%$50.40 AHCO-38.04%$6.71 BVS-0.37%$13.42

Snapshot

Index	-	P/E	52.03	EPS (ttm)	1.79	Insider Own	20.69%	Shs Outstand	12.78M	Perf Week	-1.79%

Market Cap	1.19B	Forward P/E	38.72	EPS next Y	2.40	Insider Trans	-3.93%	Shs Float	8.33M	Perf Month	-8.96%

Enterprise Value	1.15B	PEG	3.93	EPS next Q	0.54	Inst Own	-	Short Float	8.48%	Perf Quarter	9.67%

Income	23.00M	P/S	13.84	EPS this Y	16.48%	Inst Trans	-	Short Ratio	5.24	Perf Half Y	-5.93%

Sales	86.00M	P/B	15.66	EPS next Y	15.35%	ROA	20.05%	Short Interest	705.83K	Perf YTD	-4.27%

Book/sh	5.95	P/C	26.46	EPS next 5Y	13.25%	ROE	23.45%	52W High	107.90 -13.69%	Perf Year	40.74%

Cash/sh	3.52	P/FCF	46.59	EPS past 3/5Y	19.71% 73.91%	ROIC	20.18%	52W Low	66.78 39.46%	Perf 3Y	112.14%

Dividend Est.	0.80 (0.86%)	EV/EBITDA	38.25	Sales past 3/5Y	16.59% 21.29%	Gross Margin	75.86%	Volatility	4.39% 3.51%	Perf 5Y	165.71%

Dividend TTM	1.24 (1.33%)	EV/Sales	13.34	EPS Y/Y TTM	19.33%	Oper. Margin	31.91%	ATR (14)	3.52	Perf 10Y	367.99%

Dividend Ex-Date	Aug 14, 2026	Quick Ratio	9.46	Sales Y/Y TTM	17.81%	Profit Margin	26.70%	RSI (14)	46.55	Recom	2.00

Dividend Gr. 3/5Y	5.67% -	Current Ratio	9.46	EPS Q/Q	-6.12%	SMA20	-1.90%	Beta	0.90	Target Price	120.00

Payout	68.66%	Debt/Eq	0.00	Sales Q/Q	0.00%	SMA50	-1.31%	Rel Volume	1.57	Prev Close	91.56

Employees	166	LT Debt/Eq	0.03	Earnings	Nov 02	SMA200	-0.59%	Avg Volume	136.90K	Price	93.13

IPO Date	Jul 16, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.55% 0.57%	Net Debt/EBITDA	-1.92	Volume	215,020	Change	1.71%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-11-26	Reiterated	Lake Street		$100 → $120
Feb-10-26	Reiterated	Roth Capital	Buy	$98 → $120
Nov-03-25	Reiterated	Roth Capital	Buy	$90 → $98
Nov-03-25	Reiterated	Lake Street		$75 → $100
Oct-31-25	Resumed	Roth Capital	Buy	$60 → $90
Aug-02-24	Reiterated	Roth Capital	Buy	$65 → $60
Jun-17-24	Reiterated	Loop Capital Markets		$60
Jul-31-17	Upgrade	Roth Capital	Neutral → Buy
Oct-05-16	Downgrade	Roth Capital	Buy → Neutral

Latest News

Jul-31-26

Jul-31-2601:41PM

IRADIMED (NASDAQ:IRMD) Beats Q2 EPS, Reaffirms Full-Year GuidanceChartMill

01:05PM

iRadimed Q2 Earnings Call Highlightsmarketbeat.com

12:43PM

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcriptseekingalpha.com

08:15AM

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-24-26

Jul-24-2604:15PM

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026globenewswire.com

Jul-10-26

Jul-10-2608:14AM

Elon Musk Confirms Starlink Can Deliver Reliable 10 Gigabit-a-Second Upload and Download Speeds Anywhere On EarthBenzinga

Company

IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	86	84	73	66	53	42	32	39	30
Cost of Goods Sold Incl. D&A	21	19	17	15	12	10	8	9	7
Gross Profit	65	64	56	50	41	32	24	30	23
Selling, General and Administrative Excl. Other	35	35	32	27	23	20	22	20	16
Research and Development	4	3	3	3	2	2	2	1	2
Other Operating Expense	0	0	-1	0	1	0	0	0	-1
Operating Income	27	26	22	20	16	10	-1	9	6
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	2	2	2	2	1	0	0	0	0
Net Income Before Taxes	30	28	24	22	16	10	-1	9	6
Income Taxes	7	6	5	5	3	1	-2	-1	0
Consolidated Net Income	23	22	19	17	13	9	1	10	6
Net Income From Continuing Operations	12	22	19	17	13	9	1	10	6
Net Income	23	22	19	17	13	9	1	10	6
EPS (Recurring)	1.81	1.77	1.52	1.36	1.02	0.76	0.11	0.85	0.52
EPS (Basic, Before Extraordinaries)	1.81	1.77	1.52	1.36	1.02	0.76	0.11	0.85	0.52
EPS (Diluted)	1.79	1.75	1.50	1.35	1.02	0.74	0.11	0.78	0.52
EBITDA	30	31	25	23	17	11	1	10	7
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	52.03	55.59	36.67	35.16	27.74	62.45	207.27	29.97	47.04
Price To Sales Ratio	14.08	15.06	9.79	9.35	6.94	13.20	8.55	6.59	9.78
Gross Margin	75.58	76.19	76.71	75.76	77.36	76.19	75.00	76.92	76.67
Operating Margin	31.40	30.95	30.14	30.30	30.19	23.81	-3.13	23.08	20.00
Net Margin	26.74	26.19	26.03	25.76	24.53	21.43	3.13	25.64	20.00
Shares Outstanding	13	13	13	13	13	12	12	11	12
Market Capitalization	1,211	1,265	715	617	368	555	274	257	294
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GLENN JOHN	CFO	Jun 20 '26	Option Exercise	0.00	5,796	0	14,256	Jun 23
Scharen-Guivel Hilda Frederique	Director	Jun 04 '26	Sale	95.00	3,000	285,000	5,598	Jun 04
Susi Roger E.	CEO, President, Chairman	Jun 01 '26	Sale	90.60	2,500	226,507	2,162,500	Jun 02
Susi Roger E.	CEO, President, Chairman	May 27 '26	Sale	91.95	2,500	229,878	2,165,000	May 28
Susi Roger E.	CEO, President, Chairman	May 26 '26	Sale	92.23	5,000	461,166	2,167,500	May 28
Susi Roger E.	CEO, President, Chairman	May 19 '26	Sale	87.88	2,500	219,694	2,172,500	May 20
Susi Roger E.	CEO, President, Chairman	May 18 '26	Sale	87.51	5,000	437,571	2,175,000	May 20
Susi Roger E.	CEO, President, Chairman	May 12 '26	Sale	83.92	4,411	370,183	2,180,000	May 13
Susi Roger E.	CEO, President, Chairman	May 11 '26	Sale	84.54	3,089	261,158	2,184,411	May 13
Susi Roger E.	CEO, President, Chairman	May 05 '26	Sale	85.74	3,750	321,529	2,187,500	May 06
Susi Roger E.	CEO, President, Chairman	May 04 '26	Sale	85.69	3,750	321,333	2,191,250	May 06
Susi Roger E.	CEO, President, Chairman	Apr 28 '26	Sale	86.23	3,750	323,364	2,195,000	Apr 30
Susi Roger E.	CEO, President, Chairman	Apr 27 '26	Sale	89.16	3,750	334,346	2,198,750	Apr 30
Susi Roger E.	CEO, President, Chairman	Apr 21 '26	Sale	90.94	2,500	227,345	2,202,500	Apr 22
Susi Roger E.	CEO, President, Chairman	Apr 20 '26	Sale	93.36	5,000	466,779	2,205,000	Apr 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.